DD291926A5 - Verfahren zur herstellung eines mittels gegen tonsillitis - Google Patents

Verfahren zur herstellung eines mittels gegen tonsillitis Download PDF

Info

Publication number: DD291926A5
Authority: DD; German Democratic Republic
Prior art keywords: strains; streptococci; tonsillitis; streptococcal; ncib
Prior art date: 1989-02-15

Application number

DD90337852A

Other languages

German (de)

English (en)

Inventor

Eva E Grahn

Stig E F Holm

Original Assignee

��@��@��k��

��@��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-15

Filing date

1990-02-14

Publication date

1991-07-18

1990-02-14 Application filed by ��@��@��k��, ��@��@��@��k�� filed Critical ��@��@��k��

1991-07-18 Publication of DD291926A5 publication Critical patent/DD291926A5/de

Links

206010044008 tonsillitis Diseases 0.000 title abstract description 14
238000004519 manufacturing process Methods 0.000 title abstract 2
238000011282 treatment Methods 0.000 claims abstract description 20
206010044013 Tonsillitis streptococcal Diseases 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 14
239000003795 chemical substances by application Substances 0.000 claims abstract description 12
244000005700 microbiome Species 0.000 claims abstract description 12
238000002360 preparation method Methods 0.000 claims abstract description 9
238000011321 prophylaxis Methods 0.000 claims abstract description 7
230000008569 process Effects 0.000 claims abstract description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
241001134658 Streptococcus mitis Species 0.000 claims description 4
239000007921 spray Substances 0.000 claims description 4
241000194023 Streptococcus sanguinis Species 0.000 claims description 3
239000002504 physiological saline solution Substances 0.000 claims description 3
230000035899 viability Effects 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 2
235000020183 skimmed milk Nutrition 0.000 claims description 2
239000011780 sodium chloride Substances 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 abstract description 12
241000194017 Streptococcus Species 0.000 abstract description 5
239000003814 drug Substances 0.000 abstract description 5
241000282414 Homo sapiens Species 0.000 abstract description 3
230000001225 therapeutic effect Effects 0.000 abstract 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 22
230000020477 pH reduction Effects 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 9
241000894006 Bacteria Species 0.000 description 6
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
229930182555 Penicillin Natural products 0.000 description 6
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
229940049954 penicillin Drugs 0.000 description 6
238000002474 experimental method Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000000969 carrier Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
108010062877 Bacteriocins Proteins 0.000 description 3
206010018910 Haemolysis Diseases 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229960003276 erythromycin Drugs 0.000 description 3
238000002513 implantation Methods 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
239000008177 pharmaceutical agent Substances 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108090000204 Dipeptidase 1 Proteins 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010061372 Streptococcal infection Diseases 0.000 description 2
241001312524 Streptococcus viridans Species 0.000 description 2
241000394605 Viola striata Species 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
206010001093 acute tonsillitis Diseases 0.000 description 2
239000008272 agar Substances 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
102000006635 beta-lactamase Human genes 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004042 decolorization Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000005802 health problem Effects 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
FQSMJIYZTZGCPL-UHFFFAOYSA-N 1-(naphthalen-1-ylamino)pyrrolidin-2-one Chemical compound C1(=CC=CC2=CC=CC=C12)NN1C(CCC1)=O FQSMJIYZTZGCPL-UHFFFAOYSA-N 0.000 description 1
KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
MWHKPYATGMFFPI-LYYZXLFJSA-N 2-naphthyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC=C2)C2=C1 MWHKPYATGMFFPI-LYYZXLFJSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
DYFLEINNYRXWNC-UHFFFAOYSA-N 3-hydroxybutan-2-one;2-oxopropanoic acid Chemical compound CC(O)C(C)=O.CC(=O)C(O)=O DYFLEINNYRXWNC-UHFFFAOYSA-N 0.000 description 1
PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000040350 B family Human genes 0.000 description 1
108091072128 B family Proteins 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000272778 Cygnus atratus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
235000003332 Ilex aquifolium Nutrition 0.000 description 1
241000209027 Ilex aquifolium Species 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
JWHURRLUBVMKOT-HNNXBMFYSA-N L-leucine 2-naphthylamide Chemical compound C1=CC=CC2=CC(NC(=O)[C@@H](N)CC(C)C)=CC=C21 JWHURRLUBVMKOT-HNNXBMFYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
229930195708 Penicillin V Natural products 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
102000006995 beta-Glucosidase Human genes 0.000 description 1
108010047754 beta-Glucosidase Proteins 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229940093496 esculin Drugs 0.000 description 1
XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
-1 pH formation Substances 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940056367 penicillin v Drugs 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD90337852A 1989-02-15 1990-02-14 Verfahren zur herstellung eines mittels gegen tonsillitis DD291926A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8900510A SE463349B (sv)	1989-02-15	1989-02-15	Farmaceutiskt preparat foer profylax mot och/eller behandling av beta-streptokockinducerad tonsillit

Publications (1)

Publication Number	Publication Date
DD291926A5 true DD291926A5 (de)	1991-07-18

Family

ID=20375049

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90337852A DD291926A5 (de)	1989-02-15	1990-02-14	Verfahren zur herstellung eines mittels gegen tonsillitis

Country Status (28)

Country	Link
US (1)	US5378459A (fr)
EP (1)	EP0458855B1 (fr)
CN (1)	CN1046099A (fr)
AR (1)	AR247099A1 (fr)
AT (1)	ATE142503T1 (fr)
AU (1)	AU628493B2 (fr)
CA (1)	CA2047189A1 (fr)
CS (1)	CS74890A2 (fr)
DD (1)	DD291926A5 (fr)
DE (1)	DE69028520T2 (fr)
DK (1)	DK0458855T3 (fr)
EG (1)	EG19075A (fr)
ES (1)	ES2091818T3 (fr)
FI (1)	FI101452B1 (fr)
GR (1)	GR1000639B (fr)
HU (1)	HU209915B (fr)
IE (1)	IE900459L (fr)
IL (1)	IL93242A (fr)
IS (1)	IS1678B (fr)
MY (1)	MY106487A (fr)
NO (1)	NO178883C (fr)
NZ (1)	NZ232381A (fr)
PH (1)	PH27203A (fr)
PT (1)	PT93141A (fr)
SE (1)	SE463349B (fr)
WO (1)	WO1990009186A1 (fr)
YU (1)	YU23490A (fr)
ZA (1)	ZA90692B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5705152A (en) *	1990-10-26	1998-01-06	Interprise Limited	Antimicrobial composition
AUPN698495A0 (en) *	1995-12-06	1996-01-04	Pharma Pacific Pty Ltd	Improved therapeutic formulation and method
SE511648C2 (sv) *	1998-04-17	1999-11-01	Bacterum Ab	Streptokockpreparat för behandling av öroninflammation
PL206441B1 (pl)	1999-10-12	2010-08-31	Blis Technologies Ltd	Przeciwbakteryjne białko, zawierająca je kompozycja przeciwbakteryjna, preparat terapeutyczny, polinukleotydy, wyizolowany organizm, szczepy, zastosowanie białka
DE10139039A1 (de) *	2001-08-08	2003-05-08	Zinon Douvlis	Medikamentöse Suppression maligner Proliferationsprozesse durch Aminosäuren und Aminosäurenbindungen orientierte Reaktionen
EP2349295B8 (fr)	2008-11-17	2016-12-14	Winclove Holding B.V.	Préparation pharmaceutique comprenant une combinaison de souches de streptococcus et de souches de lactobacillus
US10863753B2 (en)	2015-10-01	2020-12-15	The Governing Council Of The University Of Toronto	Iron-fortified tea preparations and methods of making same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4454109A (en) *	1981-02-17	1984-06-12	Forsyth Dental Infirmary For Children	Method of treating periodontosis
CA1195613A (fr) *	1981-02-17	1985-10-22	Forsyth Dental Infirmary For Children	Methode traitement de la periodontose
JPS5927833A (ja) *	1982-08-06	1984-02-14	Advance Res & Dev Co Ltd	コレステロール乃至トリグリセリド低下剤

1989
- 1989-02-15 SE SE8900510A patent/SE463349B/sv not_active IP Right Cessation
1990
- 1990-01-30 ZA ZA90692A patent/ZA90692B/xx unknown
- 1990-02-01 IL IL9324290A patent/IL93242A/en not_active IP Right Cessation
- 1990-02-05 NZ NZ232381A patent/NZ232381A/en unknown
- 1990-02-07 YU YU23490A patent/YU23490A/sh unknown
- 1990-02-08 PH PH40021A patent/PH27203A/en unknown
- 1990-02-09 IE IE900459A patent/IE900459L/xx unknown
- 1990-02-12 ES ES90903444T patent/ES2091818T3/es not_active Expired - Lifetime
- 1990-02-12 WO PCT/SE1990/000089 patent/WO1990009186A1/fr not_active Ceased
- 1990-02-12 DE DE69028520T patent/DE69028520T2/de not_active Expired - Fee Related
- 1990-02-12 CA CA002047189A patent/CA2047189A1/fr not_active Abandoned
- 1990-02-12 DK DK90903444.9T patent/DK0458855T3/da active
- 1990-02-12 AT AT90903444T patent/ATE142503T1/de not_active IP Right Cessation
- 1990-02-12 GR GR900100092A patent/GR1000639B/el unknown
- 1990-02-12 AU AU51577/90A patent/AU628493B2/en not_active Ceased
- 1990-02-12 EP EP90903444A patent/EP0458855B1/fr not_active Expired - Lifetime
- 1990-02-12 HU HU901920A patent/HU209915B/hu not_active IP Right Cessation
- 1990-02-13 EG EG7290A patent/EG19075A/xx active
- 1990-02-14 PT PT93141A patent/PT93141A/pt not_active Application Discontinuation
- 1990-02-14 DD DD90337852A patent/DD291926A5/de unknown
- 1990-02-14 IS IS3547A patent/IS1678B/is unknown
- 1990-02-15 AR AR90316173A patent/AR247099A1/es active
- 1990-02-15 MY MYPI90000256A patent/MY106487A/en unknown
- 1990-02-15 CN CN90101773A patent/CN1046099A/zh active Pending
- 1990-02-15 CS CS90748A patent/CS74890A2/cs unknown
1991
- 1991-08-13 NO NO913162A patent/NO178883C/no not_active IP Right Cessation
- 1991-08-14 FI FI913845A patent/FI101452B1/fi active
1994
- 1994-02-10 US US08/194,753 patent/US5378459A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO913162D0 (no)	1991-08-13
CS74890A2 (en)	1991-09-15
EG19075A (en)	1994-06-30
SE463349B (sv)	1990-11-12
PT93141A (pt)	1990-08-31
PH27203A (en)	1993-05-04
IS1678B (is)	1997-12-31
EP0458855B1 (fr)	1996-09-11
IE900459L (en)	1990-08-15
SE8900510L (sv)	1990-08-16
GR900100092A (en)	1991-06-28
YU23490A (sh)	1993-05-28
IL93242A0 (en)	1990-11-29
IL93242A (en)	1994-11-28
AU5157790A (en)	1990-09-05
SE8900510D0 (sv)	1989-02-15
NO178883B (no)	1996-03-18
GR1000639B (el)	1992-09-11
HU209915B (en)	1994-11-28
FI101452B (fi)	1998-06-30
FI101452B1 (fi)	1998-06-30
DE69028520D1 (de)	1996-10-17
FI913845A0 (fi)	1991-08-14
NO178883C (no)	1996-06-26
ZA90692B (en)	1990-10-31
DK0458855T3 (da)	1996-09-30
EP0458855A1 (fr)	1991-12-04
AR247099A1 (es)	1994-11-30
ES2091818T3 (es)	1996-11-16
AU628493B2 (en)	1992-09-17
IS3547A7 (is)	1990-08-16
MY106487A (en)	1995-06-30
NO913162L (no)	1991-10-07
CN1046099A (zh)	1990-10-17
US5378459A (en)	1995-01-03
NZ232381A (en)	1992-10-28
HUT57051A (en)	1991-11-28
CA2047189A1 (fr)	1990-08-16
DE69028520T2 (de)	1997-04-03
WO1990009186A1 (fr)	1990-08-23
ATE142503T1 (de)	1996-09-15

Legal Events

Date	Code	Title	Description
2004-04-28	IF04	In force in the year 2004	Expiry date: 20100215

Publication	Publication Date	Title
DE69501591T2 (de)	1998-06-10	Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
CA1246445A (fr)	1988-12-13	Agent ameliorant la flore intentinale
DE69025953T2 (de)	1996-09-05	Pharmazeutische zubereitung zur kontrolle pathogener intestinaler bakterien
DE69223615T2 (de)	1998-04-09	Lactobacillus Acidophilus enthaltende Antigastritis-Mittel
US5951977A (en)	1999-09-14	Competitive exclusion culture for swine
DE69219768T2 (de)	1997-08-28	Milchbakterien
DE69623991T2 (de)	2003-08-07	Hemmung des bakterienwachstums in absorbierenden gegenständen durch zugabe an deser bakterien
US20220409681A1 (en)	2022-12-29	Lactobacillus salivarius ls97 and application thereof
CH653556A5 (de)	1986-01-15	Arzneimittel mit antitumor-wirkung.
DE2813733A1 (de)	1978-10-12	Verfahren zur herstellung von nahrungsmitteln und getraenken mit einem gehalt an bifidobakterien
DD291926A5 (de)	1991-07-18	Verfahren zur herstellung eines mittels gegen tonsillitis
DE60018591T2 (de)	2006-04-13	Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
DE60037343T2 (de)	2008-11-27	Bifidobakterien mit der fähigkeit diarrhoe zu verhindern
CH650645A5 (de)	1985-08-15	Diaetetisches mittel.
DE1492135A1 (de)	1969-06-12	Verfahren zur Herstellung von Medikamenten fuer die Regenerierung der Darmmikroflora
Iveson	1973	Enrichment procedures for the isolation of Salmonella, Arizona, Edwardsiella and Shigella from faeces
DE1492779C3 (de)	1974-05-22	Verfahren zum Herstellen von Sauermilchprodukten
DE102022003908A1 (de)	2023-08-03	Milchsäurebaktieren-zusammensetzung und ihre verwendung als medikament zur inhibierung von arzneimittel-resistenten enterobacteriaceae
DE2011935C3 (de)	1975-02-27	Enzym mit der Fähigkeit zur Lyse der Zellen von Zahnkaries erzeugenden Mikroorganismen, Verfahren zur Herstellung dieses Enzyms sowie ein Präparat zur Verhütung und Behandlung von Zahnkaries
DE3505311C2 (de)	1987-05-07	Selektives Mittel für Streptokokken der Gruppe A.
DE2040440B2 (de)	1977-07-14	Enzym, mit der faehigkeit zur lyse der zellen von zahnkaries erzeugenden mikroorganismen, verfahren zur herstellung desselben und dasselbe enthaltende praeparat zur verhuetung und behandlung von zahnkaries
RU2063436C1 (ru)	1996-07-10	Штамм lactobacillus acidophilus - антибиотикорезистентный антагонист возбудителей кишечных инфекций
WO2005117923A1 (fr)	2005-12-15	Bioprotection
CN118652819A (zh)	2024-09-17	一株枯草芽孢杆菌及其发酵产物和应用
McGhie et al.	1976	Laboratory and clinical studies with mecillinam